Brittany Abshire
Psychiatric/Mental Health · Staunton, VANPI 1730619099
Payments from drug & device makers
Across 268 payments — averaging $17.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$1K
- Johnson & Johnson$786
- Otsuka America Pharmaceutical, Inc.$567
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$555
- Teva Pharmaceuticals USA, Inc.$432
- E.r. Squibb & Sons, L.L.C.$248
- plus $755 from 7 others
What the payments were for
- Food & beverage$4,630100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 93 | $1,287 |
| Johnson & Johnson | 36 | $786 |
| Otsuka America Pharmaceutical, Inc. | 28 | $567 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 41 | $555 |
| Teva Pharmaceuticals USA, Inc. | 22 | $432 |
| E.r. Squibb & Sons, L.L.C. | 8 | $248 |
| Axsome Therapeutics, Inc. | 6 | $197 |
| AbbVie | 10 | $192 |
| Alkermes, Inc. | 12 | $184 |
| Lundbeck LLC | 6 | $89 |
| Vanda Pharmaceuticals Inc. | 3 | $47 |
| Indivior Inc. | 2 | $30 |
| Merck | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,630 in reported general payments places this provider in the 90th percentile of 1,003 psychiatric/mental health providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 118 | $408,344 |
| IngrezzaValbenazine Tosylate | 47 | $372,017 |
| VraylarCariprazine Hcl | 169 | $268,214 |
| AristadaAripiprazole Lauroxil | 61 | $201,834 |
| Austedo XrDeutetrabenazine | 28 | $169,152 |
| CaplytaLumateperone Tosylate | 76 | $128,311 |
| Invega TrinzaPaliperidone Palmitate | 11 | $124,189 |
| VivitrolNaltrexone Microspheres | 55 | $93,909 |
| RexultiBrexpiprazole | 33 | $53,372 |
| Abilify MaintenaAripiprazole | 17 | $49,114 |
| TrintellixVortioxetine Hydrobromide | 69 | $32,163 |
| Lurasidone Hcl | 98 | $12,620 |
| Aripiprazole | 101 | $11,731 |
| Paliperidone ErPaliperidone | 18 | $10,797 |
| VyvanseLisdexamfetamine Dimesylate | 17 | $8,136 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza | $786 | $532,533129 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,287 | $372,01747 claims |
| Alkermes, Inc.Aristada, Vivitrol | $184 | $295,743116 claims |
| AbbVieVraylar | $192 | $268,214169 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $432 | $169,15228 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $555 | $128,31176 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $567 | $102,48750 claims |
| MerckBelsomra | $16 | $4,92011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,003 psychiatric/mental health providers in Virginia.
Other psychiatric/mental health in Staunton
- Brooks FloydStaunton$10K
- Pamela HevenerStaunton$9K
- Justin RayChesapeake$127K
- Katia HallChesapeake$88K
- Christine GilmoreBedford$75K
- Sarah FaberNewport News$59K
- Kristine GarciaGlen Allen$46K
- Tonjanika BoydRichmond$40K
- Kirby PatmonRichmond$36K
- Juliana FroschAmherst$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.